---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-010776"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:36:30.373668+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv Q3 revenue $2.0M (down 17% YoY); net loss narrows to $0.2M

## Summary
- Revenue for three months ended July 31, 2025 was $2.0M, down from $2.4M in the same period last year.
- Net loss for Q3 was $0.2M, an improvement of $0.1M compared to a $0.3M loss in Q3 2024.
- Nine-month revenue was $6.9M vs $7.2M YoY; net loss $0.1M, improvement of $0.7M.
- CEO cites cost streamlining and preparation for imminent start of several significant projects.

## SEC filing metadata
- accession: 0001654954-25-010776
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495425010776/0001654954-25-010776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495425010776/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-010776
- JSON: https://secwatch.observer/filing/0001654954-25-010776.json
- Plain text: https://secwatch.observer/filing/0001654954-25-010776.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.